PROSTATE CANCER
 
Could mpMRI replace prostate Bx for surveillance protocols?
"Even in this selected cohort of men with very low-risk features, stable MRI score was not protective against disease progression during surveillance," writes Badar M. Mian, MD.
Read his column
 
PSMA-targeted therapy well tolerated in men with mCRPC
A radiolabeled small molecule that binds to prostate-specific membrane antigen is continuing to show promise for treating progressive metastatic castrate-resistant prostate cancer, according to researchers at the University of California, Los Angeles.
Learn more
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
 
MORE FROM UROLOGY TIMES
 
Oral advanced prostate cancer agent shows safety, efficacy
PARP inhibitors may mark new era in prostate cancer care
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont